2. Cell Cycle/DNA Damage Antibody-drug Conjugate/ADC Related Anti-infection Apoptosis
  3. DNA Alkylator/Crosslinker DNA/RNA Synthesis ADC Payload Bacterial Apoptosis Antibiotic
  4. Mitomycin C

Mitomycin C  (Synonyms: 丝裂霉素 C ; Ametycine)

目录号: HY-13316 纯度: 99.70%
COA 产品使用指南 技术支持

Mitomycin C (Ametycine) 是一种 DNA 交联剂 (DNA cross-linking agent)，诱导 DNA 损伤。Mitomycin C 是一种抗肿瘤化合物和抗生素，可有效的抑制 DNA 合成 (DNA synthesis)。Mitomycin C 是一种 ADC 毒性分子 (ADC Cytotoxin)，可以诱导凋亡 (Apoptosis) 作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 50-07-7

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
5 mg ￥493
In-stock
10 mg ￥780
In-stock
50 mg ￥2000
In-stock
100 mg ￥3000
询价
200 mg ￥4850
In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

Customer Review

Mitomycin C 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 141 篇科研文献

Proliferation Assay
RT-PCR
Cell Viability Assay

    Mitomycin C purchased from MCE. Usage Cited in: Adv Mater. 2024 May 9:e2401361.  [Abstract]

    qPCR results of senescence-associated secretory phenotype (SASP) mRNA expression levels in cells. Control and mitomycin C (MMC) stand for normal and senescent cells. Concentrations of D-PtPd2CuFe represent the treatment senescent cells received.

    Mitomycin C purchased from MCE. Usage Cited in: NPJ Biofilms Microbiomes. 2023 Oct 11;9(1):79.  [Abstract]

    Mitomycin C (0 or 0.5 μg/mL; 24 h) significantly induces cell lysis of E. coli ATCC 25922.

    Mitomycin C purchased from MCE. Usage Cited in: Nat Commun. 2022 Aug 16;13(1):4822.  [Abstract]

    Mitomycin C (MMC) (1 μM; 6 days) significantly suppresses mRNA levels of SASP genes (including Il1b, Il8, Il6, and p21waf1) in Irf8-deficient BMDMs.

    Mitomycin C purchased from MCE. Usage Cited in: Adv Healthc Mater. 2019 Sep;8(18):e1900543.  [Abstract]

    Cytotoxicity of different DOX/MMC formulations in DOX:MMC molar ratio of 1.0:0.7 against a) MDA-MB-231-luc-D3H2LN cells. Cells were treated for 1 h with various DOX/MMC concentrations of free DOX/MMC or DMTPLN or iRGD-DMTPLN, or blank iRGD-TPLN with same concentration of the NP. X-axes based on DOX concentration. Cells were allowed to proliferate for 24 h before being evaluated for viability by MTT assay.

    Mitomycin C purchased from MCE. Usage Cited in: Adv Healthc Mater. 2019 Sep;8(18):e1900543.  [Abstract]

    Cytotoxicity of different DOX/MMC formulations in DOX:MMC molar ratio of 1.0:0.7 against RAW 264.7 macrophages. Cells were treated for 1 h with various DOX/MMC concentrations of free DOX/MMC or DMTPLN or iRGD-DMTPLN, or blank iRGD-TPLN with same concentration of the NP. X-axes based on DOX concentration. Cells were allowed to proliferate for 24 h before being evaluated for viability by MTT assay.

    Mitomycin C purchased from MCE. Usage Cited in: Sci Rep. 2017 Jun 30;7(1):4469.  [Abstract]

    In order to normalize the potential effect of cell proliferation, Mitomycin C is added to the culture media to make the cells uniformly arrested. The results show that all migration cell indexes reduced after adding Mitomycin C than those observed without Mitomycin C. Knockdown of RAD51-AS1 still inhibits cell migration (A) and invasion of SKOV3, SKOV3.ip and HO8910 cells (B), while overexpression of RAD51-AS1 only increased cell invasion capacity of the OVCAR3 cells, not in the Hey cells (C).

    Mitomycin C purchased from MCE. Usage Cited in: Exp Cell Res. 2016 Feb 15;341(2):157-65.  [Abstract]

    Curcumin inhibits the migration of BCPAP cells. Migration of cancer cells is assayed by wound-healing assay. Cells are cultured to nearly confluent cell monolayer and pretreated with Mitomycin C (10 μg/mL) for 2 h, followed by either DMSO or different dosages of curcumin for 6 h, before cells are wounded using yellow pipette tips. The cells are washed with PBS, and cultured for additional 24 h at 37 °C. (A) Photographs are taken after wound initially made and healing for 24 h. Data are represent

    查看 ADC Payload 亚型特异性产品:

    查看所有亚型
    Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

    查看 Antibiotic 亚型特异性产品:

    查看所有亚型
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Mitomycin C (Ametycine) is a DNA cross-linking agent and induces DNA damaging. Mitomycin C is an antitumor agent and antibiotic that shows extraordinary ability to inhibit DNA synthesis. Mitomycin C is an ADC Cytotoxin and induces apoptosis[1][2][3].

    IC50 & Target

    Traditional Cytotoxic Agents

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    786-0 GI50
    0.21 μM
    Compound: Mitomycin
    Growth inhibition of human 786-O cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human 786-O cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    833K IC50
    0.328 μM
    Compound: MMC
    Inhibition of cell growth was studied in human teratocarcinoma (833K).
    Inhibition of cell growth was studied in human teratocarcinoma (833K).
    		[PMID: 8709111]
    A2780 IC50
    0.05 μM
    Compound: Mitomycin C
    The compound was evaluated for the cytotoxicity against human A2780 (ovarian) tumor cell lines.
    The compound was evaluated for the cytotoxicity against human A2780 (ovarian) tumor cell lines.
    		[PMID: 10698444]
    A2780 IC50
    0.18 μM
    Compound: 2
    Cytotoxicity against human A2780 cells
    Cytotoxicity against human A2780 cells
    		[PMID: 35567964]
    A2780 IC50
    0.18 μM
    Compound: MMC; MCC
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33581556]
    A2780 IC50
    100 nM
    Compound: mitomycin C
    In vitro inhibition of 2780/S ovarian cancer cell line
    In vitro inhibition of 2780/S ovarian cancer cell line
    		[PMID: 1920349]
    A2780 IC50
    200 nM
    Compound: mitomycin C
    In vitro inhibition of 2780/DOX ovarian cancer cell line
    In vitro inhibition of 2780/DOX ovarian cancer cell line
    		[PMID: 1920349]
    A2780cisR IC50
    0.06 μM
    Compound: Mitomycin C
    The compound was evaluated for the cytotoxicity against human A2780cisR (ovarian) tumor cell lines.
    The compound was evaluated for the cytotoxicity against human A2780cisR (ovarian) tumor cell lines.
    		[PMID: 10698444]
    A549 EC50
    0.43 μM
    Compound: Mitomycin
    Cytotoxicity against human A549 cells assessed as cell viability by tryptan blue staining method
    Cytotoxicity against human A549 cells assessed as cell viability by tryptan blue staining method
    		[PMID: 17950604]
    A549 EC50
    0.43 μM
    Compound: mitomycin
    Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay
    Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay
    		[PMID: 19674905]
    A549 EC50
    5.2 μM
    Compound: MMC
    Cytotoxicity against human A549 cells assessed as decrease in cell viability at 10 to 100 uM after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability at 10 to 100 uM after 48 hrs by SRB assay
    		[PMID: 26508550]
    A549 GI50
    0.08 μM
    Compound: Mitomycin
    Growth inhibition of human A549 cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human A549 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    A549 IC50
    0.015 μg/mL
    Compound: Mitomycin c
    Antitumor activity against A549 human lung carcinoma cell line in experiment 1
    Antitumor activity against A549 human lung carcinoma cell line in experiment 1
    		[PMID: 2754710]
    A549 IC50
    0.02 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 12662110]
    A549 IC50
    0.04 μM
    Compound: Mitomycin-C
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 25259515]
    A549 IC50
    0.08 μg/mL
    Compound: 1
    in vitro anticancer activity against cultured A549 human tumor(lung) cell line
    in vitro anticancer activity against cultured A549 human tumor(lung) cell line
    		[PMID: 11585450]
    A549 IC50
    0.08 μg/mL
    Compound: Mitomycin c
    Antitumor activity against A549 human lung carcinoma cell line in experiment 2
    Antitumor activity against A549 human lung carcinoma cell line in experiment 2
    		[PMID: 2754710]
    A549 IC50
    0.24 μM
    Compound: MMC, mitomycin c
    Cytotoxicity against human A549 cells after 72 hrs
    Cytotoxicity against human A549 cells after 72 hrs
    		[PMID: 18037301]
    A549 IC50
    0.27 μM
    Compound: Mitomycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31490685]
    A549 IC50
    0.3 μM
    Compound: Mitomycin C
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    Cytotoxicity against human A549 cells after 3 days by SRB assay
    		[PMID: 16038545]
    A549 IC50
    0.4 μM
    Compound: MMC
    Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
    Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
    		[PMID: 23123017]
    A549 IC50
    0.4 μM
    Compound: MMC, mitomycin c
    Cytotoxicity against human A549 cells by Alamar blue assay
    Cytotoxicity against human A549 cells by Alamar blue assay
    		[PMID: 18037301]
    A549 IC50
    0.4 μM
    Compound: Mitomycin-C
    Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0424-0
    A549 IC50
    0.4 μM
    Compound: Mitomycin-C
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
    		10.1039/C3MD00055A
    A549 IC50
    0.4 μM
    Compound: mitomycin C
    Cytotoxicity against human A549 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human A549 cells after 72 hrs by Alamar Blue assay
    		[PMID: 18752870]
    A549 IC50
    0.45 μM
    Compound: Mitomycin C
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by WST8 assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by WST8 assay
    		[PMID: 25442306]
    A549 IC50
    0.47 μg/mL
    Compound: Mitomycin c
    Antitumor activity against A549 human lung carcinoma cell line
    Antitumor activity against A549 human lung carcinoma cell line
    		[PMID: 2754710]
    A549 IC50
    0.5 μM
    Compound: Mitomycin C
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 27089214]
    A549 IC50
    0.54 μg/mL
    Compound: Mitomycin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay
    		[PMID: 23451797]
    A549 IC50
    0.63 μM
    Compound: 2
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 35567964]
    A549 IC50
    0.63 μM
    Compound: MMC; MCC
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33581556]
    A549 IC50
    1.7 μM
    Compound: Mitomycin
    Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay
    		[PMID: 26615890]
    A549 IC50
    11.03 μM
    Compound: Mitomycin C
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 31761382]
    A549 IC50
    15.525 μM
    Compound: 1
    Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay
    		[PMID: 28395199]
    A549 IC50
    2.75 μM
    Compound: Mitomycin C
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34847663]
    A549 IC50
    3 μM
    Compound: mitomycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 22545792]
    A549 IC50
    4.5 μM
    Compound: MMC, mitomycin c
    Cytotoxicity against human A549 cells after 24 hrs
    Cytotoxicity against human A549 cells after 24 hrs
    		[PMID: 18037301]
    B16 IC50
    3.6 μg/mL
    Compound: Mitomycin c
    Antitumor activity against B16-BN murine melanoma cell line
    Antitumor activity against B16-BN murine melanoma cell line
    		[PMID: 2754710]
    B16-F10 IC50
    1.5 μg/mL
    Compound: Mitomycin c
    Antitumor activity against B16-F10 murine melanoma cell line
    Antitumor activity against B16-F10 murine melanoma cell line
    		[PMID: 2754710]
    BXPC-3 GI50
    0.38 μM
    Compound: Mitomycin
    Growth inhibition of human BxPC3 cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human BxPC3 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    Bcap37 IC50
    2.33 μg/mL
    Compound: Mitomycin
    Antitumor activity against human Bcap37 cell line by MTT assay
    Antitumor activity against human Bcap37 cell line by MTT assay
    		[PMID: 16455245]
    BeWo IC50
    0.06 μM
    Compound: Mitomycin
    Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27010926]
    BeWo IC50
    0.85 μg/mL
    Compound: (21) mitomycin
    In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    CAKI-1 IC50
    251 nM
    Compound: Mitomycin C
    Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 4th hour; n=1
    Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 4th hour; n=1
    		[PMID: 15743178]
    CAKI-1 IC50
    40 nM
    Compound: Mitomycin C
    Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 96th hour; n=14
    Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 96th hour; n=14
    		[PMID: 15743178]
    CCD 19Lu IC50
    2 μg/mL
    Compound: Mitomycin C (MMC)
    Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
    Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
    		10.1016/S0960-894X(97)00071-1
    CCRF S-180 ED50
    1.7 mg/kg
    Compound: mitomycin C
    Effective dose that gave 50 percent inhibition of sarcoma 180 tumor growth in ddY mice
    Effective dose that gave 50 percent inhibition of sarcoma 180 tumor growth in ddY mice
    		[PMID: 8021919]
    CCRF S-180 ED50
    4.4 μg/mL
    Compound: 30
    Antitumor activity against mouse S180 cells implanted in ip dosed ddY mouse assessed as tumor volume after 7 days
    Antitumor activity against mouse S180 cells implanted in ip dosed ddY mouse assessed as tumor volume after 7 days
    		[PMID: 19540628]
    CCRF-CEM IC50
    0.02 μg/mL
    Compound: Mitomycin C (MMC)
    Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
    Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
    		10.1016/S0960-894X(97)00071-1
    CH1 IC50
    0.04 μM
    Compound: Mitomycin C
    The compound was evaluated for the cytotoxicity against human CH1 (ovarian) tumor cell lines.
    The compound was evaluated for the cytotoxicity against human CH1 (ovarian) tumor cell lines.
    		[PMID: 10698444]
    CHO-AA8 IC50
    1.08 nM
    Compound: Mitomycin C
    Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)
    Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)
    		[PMID: 2909741]
    CHO-K1 IC50
    13.1 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
    		[PMID: 31195172]
    CHO-K1 IC50
    13.2 μM
    Compound: Mitomycin c
    Cytotoxicity against CHOK1 cells incubated for 24 hrs by MTT asasy
    Cytotoxicity against CHOK1 cells incubated for 24 hrs by MTT asasy
    		[PMID: 28615134]
    CHO-K1 IC50
    39.8 μM
    Compound: Mitomycin C
    Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    		[PMID: 31858800]
    CNE-2 IC50
    > 10 μM
    Compound: Mitomycin C
    Antiproliferative activity against human CNE2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human CNE2 cells after 48 hrs by MTT assay
    		[PMID: 29280632]
    Ca-Ski IC50
    > 10 μM
    Compound: Mitomycin C
    Antiproliferative activity against human CaSki cells after 48 hrs by MTT assay
    Antiproliferative activity against human CaSki cells after 48 hrs by MTT assay
    		[PMID: 29280632]
    Caco-2 IC50
    5.8 μM
    Compound: Mitomycin
    Cytotoxicity against human Caco2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human Caco2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31490685]
    Cancer cell lines GI50
    0.023 μM
    Compound: mitomycin C
    Cytotoxicity against human lung cancer cells
    Cytotoxicity against human lung cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    0.034 μM
    Compound: mitomycin C
    Cytotoxicity against human breast cancer cells
    Cytotoxicity against human breast cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    0.064 μM
    Compound: mitomycin C
    Cytotoxicity against human CNS cancer cells
    Cytotoxicity against human CNS cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    0.1 μM
    Compound: mitomycin C
    Cytotoxicity against human stomach cancer cells
    Cytotoxicity against human stomach cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    0.12 μM
    Compound: mitomycin C
    Cytotoxicity against human ovarian cancer cells
    Cytotoxicity against human ovarian cancer cells
    		[PMID: 11473418]
    Cancer cell lines GI50
    0.18 μM
    Compound: mitomycin C
    Cytotoxicity against human colon cancer cells
    Cytotoxicity against human colon cancer cells
    		[PMID: 11473418]
    Clone 62 IC50
    1.5 μM
    Compound: 1
    Inhibitory activity against clone62, a mouse melanoma cell line in absence of Enterobacter cloacae bL
    Inhibitory activity against clone62, a mouse melanoma cell line in absence of Enterobacter cloacae bL
    		[PMID: 9276025]
    DC3F IC50
    0.082 μM
    Compound: MMC
    Inhibition of cell growth was studied in chinese hamster lung cells (DC-3F)
    Inhibition of cell growth was studied in chinese hamster lung cells (DC-3F)
    		[PMID: 8709111]
    DLD-1 ED50
    0.1 μg/mL
    Compound: mitomycin
    Cytotoxicity against human DLD1 cells after 3 days by methylene blue staining
    Cytotoxicity against human DLD1 cells after 3 days by methylene blue staining
    		[PMID: 16309320]
    DU-145 IC50
    0.17 μM
    Compound: MMC
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
    		[PMID: 20605274]
    DU-145 IC50
    0.17 μM
    Compound: MMC, NSC-26980
    Cytotoxicity against human DU145 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay
    		[PMID: 22522008]
    DU-145 IC50
    1.8 μM
    Compound: Mitomycin C
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) DU145 cells by SRB assay
    		10.1007/s00044-010-9500-5
    Daoy ED50
    0.08 μg/mL
    Compound: Mitomycin-C
    Antiproliferative activity against human DaOY cells after 6 days by MTT assay
    Antiproliferative activity against human DaOY cells after 6 days by MTT assay
    		[PMID: 22672798]
    Daoy ED50
    0.14 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human DaOY cells by MTT assay
    Cytotoxicity against human DaOY cells by MTT assay
    		[PMID: 20144547]
    Daoy ED50
    0.1 μg/mL
    Compound: mitomycin C
    Cytotoxicity against human DaOY cells after 3 days by MTT assay
    Cytotoxicity against human DaOY cells after 3 days by MTT assay
    		[PMID: 21115251]
    Daoy ED50
    0.21 μM
    Compound: mitomycin C
    Cytotoxicity against human Daoy cells by MTT assay
    Cytotoxicity against human Daoy cells by MTT assay
    		[PMID: 19061391]
    Daoy IC50
    0.05 μg/mL
    Compound: Mitomycin
    Cytotoxicity against human DaOY cells after 1 to 11 days by MTT assay
    Cytotoxicity against human DaOY cells after 1 to 11 days by MTT assay
    		[PMID: 22014827]
    Daudi IC50
    0.45 μM
    Compound: Mitomycin C
    Growth inhibition of human Daudi cells after 24 to 72 hrs by MTT assay
    Growth inhibition of human Daudi cells after 24 to 72 hrs by MTT assay
    		[PMID: 20117936]
    EL4 IC50
    0.06 μM
    Compound: Mitomycin
    Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 27010926]
    EL4 IC50
    3.94 μg/mL
    Compound: (21) mitomycin
    In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    EMT6 ED50
    0.001 μM
    Compound: mytomycin C
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.
    		[PMID: 7452674]
    EMT6 ED50
    0.7 μM
    Compound: mytomycin C
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
    Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.
    		[PMID: 7452674]
    Fibroblast EC50
    0.93 μM
    Compound: mitomycin
    Antiproliferative activity against human skin fibroblast after 72 hrs by trypan blue exclusion assay
    Antiproliferative activity against human skin fibroblast after 72 hrs by trypan blue exclusion assay
    		[PMID: 19674905]
    GES1 IC50
    21.12 μM
    Compound: Mitomycin C
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 31761382]
    HCT-116 GI50
    0.2 μM
    Compound: Mitomycin
    Growth inhibition of human HCT116 cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human HCT116 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    HCT-116 IC50
    0.015 μg/mL
    Compound: Mitomycin c
    Antitumor activity against HCT116 human colon carcinoma cell line experiment 1
    Antitumor activity against HCT116 human colon carcinoma cell line experiment 1
    		[PMID: 2754710]
    HCT-116 IC50
    0.01 μg/mL
    Compound: Mitomycin c
    Antitumor activity against HCT116 human colon carcinoma cell line experiment 2
    Antitumor activity against HCT116 human colon carcinoma cell line experiment 2
    		[PMID: 2754710]
    HCT-116 IC50
    0.5 μM
    Compound: Mytomycine
    Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 23501113]
    HCT-116 IC50
    0.55 μM
    Compound: Mitomycin C
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34847663]
    HCT-116 IC50
    0.56 μM
    Compound: 2
    Cytotoxicity against human HCT-116 cells
    Cytotoxicity against human HCT-116 cells
    		[PMID: 35567964]
    HCT-116 IC50
    0.56 μM
    Compound: MMC; MCC
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33581556]
    HCT-116 IC50
    1.1 μg/mL
    Compound: Mitomycin c
    Antitumor activity against HCT116 human colon carcinoma cell line
    Antitumor activity against HCT116 human colon carcinoma cell line
    		[PMID: 2754710]
    HCT-116 IC50
    11.03 μM
    Compound: Mitomycin C
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 31761382]
    HCT-15 IC50
    0.07 μM
    Compound: Mitomycin C
    In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    HCT-15 IC50
    0.5 μM
    Compound: Mitomycin
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 24910974]
    HCT-8 IC50
    0.083 μM
    Compound: MMC
    Cytotoxicity against human HCT8 cells after 72 hrs by SRB assay
    Cytotoxicity against human HCT8 cells after 72 hrs by SRB assay
    		[PMID: 18845441]
    HCT-8 IC50
    0.15 μg/mL
    Compound: 1
    in vitro inhibition of tumor cell growth in cultured HCT-8 human tumor cell line
    in vitro inhibition of tumor cell growth in cultured HCT-8 human tumor cell line
    		[PMID: 11585450]
    HCT-8 IC50
    0.6 μM
    Compound: Mitomycin C
    Cytotoxicity against human HCT8 cells after 3 days by SRB assay
    Cytotoxicity against human HCT8 cells after 3 days by SRB assay
    		[PMID: 16038545]
    HEp-2 ED50
    0.07 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human Hep2 cells by MTT assay
    Cytotoxicity against human Hep2 cells by MTT assay
    		[PMID: 20144547]
    HEp-2 ED50
    0.12 μg/mL
    Compound: Mitomycin-C
    Antiproliferative activity against human Hep2 cells after 6 days by MTT assay
    Antiproliferative activity against human Hep2 cells after 6 days by MTT assay
    		[PMID: 22672798]
    HEp-2 ED50
    0.1 μg/mL
    Compound: mitomycin C
    Cytotoxicity against human Hep2 cells after 3 days by MTT assay
    Cytotoxicity against human Hep2 cells after 3 days by MTT assay
    		[PMID: 21115251]
    HEp-2 IC50
    1.5 μM
    Compound: Mto-C
    Growth inhibition of human Hep2 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human Hep2 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19939522]
    HL-60 IC50
    0.05 μM
    Compound: MMC
    Inhibition of cell growth was studied in human promyelocytic leukemic (HL-60) cells.
    Inhibition of cell growth was studied in human promyelocytic leukemic (HL-60) cells.
    		[PMID: 8709111]
    HL-60 IC50
    0.1 μM
    Compound: MMC
    Cytotoxicity against human HL60 cells after 72 hrs by WST8 assay
    Cytotoxicity against human HL60 cells after 72 hrs by WST8 assay
    		[PMID: 22537363]
    HL-60 IC50
    0.19 μM
    Compound: MMC
    Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay
    		[PMID: 29475587]
    HL-60 IC50
    1.5 μM
    Compound: Mitomycin
    Cytotoxicity against human HL60 by MTT assay
    Cytotoxicity against human HL60 by MTT assay
    		[PMID: 20968296]
    HL-60 IC50
    1.5 μM
    Compound: mitomycin
    Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
    Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
    		[PMID: 19432411]
    HL-60 IC50
    1.8 μM
    Compound: mitomycin C
    Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
    Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
    		[PMID: 22642381]
    HL-60 IC50
    3 μM
    Compound: Mitomycin
    Cytotoxicity against human HL60 cells after 48 hrs by SRB method
    Cytotoxicity against human HL60 cells after 48 hrs by SRB method
    		[PMID: 24913558]
    HL-60 IC50
    410 nM
    Compound: MC
    Antiproliferative activity against human HL60 cells after 48 hrs by resazurin reduction assay
    Antiproliferative activity against human HL60 cells after 48 hrs by resazurin reduction assay
    		[PMID: 26541587]
    HT-1080 IC50
    0.15 μg/mL
    Compound: Mitomycin
    Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay
    Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay
    		[PMID: 23451797]
    HT-29 IC50
    0.02 μg/mL
    Compound: (21) mitomycin
    In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    HT-29 IC50
    0.04 μM
    Compound: Mitomycin C
    The compound was evaluated for the cytotoxicity against human HT-29 (colon) tumor cell lines.
    The compound was evaluated for the cytotoxicity against human HT-29 (colon) tumor cell lines.
    		[PMID: 10698444]
    HT-29 IC50
    0.06 μM
    Compound: Mitomycin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27010926]
    HT-29 IC50
    0.06 μM
    Compound: Mitomycin
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 27010926]
    HT-29 IC50
    0.44 μM
    Compound: Mitomycin C
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34847663]
    HT-29 IC50
    0.9 μM
    Compound: mitomycin C
    Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
    		[PMID: 18222567]
    HT-29 IC50
    2.1 μM
    Compound: mitomycin C
    Cytotoxicity against human HT29 cells after 72 hrs by MTT assay in presence of 2 uM dicoumarol
    Cytotoxicity against human HT29 cells after 72 hrs by MTT assay in presence of 2 uM dicoumarol
    		[PMID: 18222567]
    HT-29 IC50
    7.099 μM
    Compound: 1
    Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay
    		[PMID: 28395199]
    HT-29 IC50
    99 nM
    Compound: Mitomycin C
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    		[PMID: 2778449]
    HeLa ED50
    0.13 μg/mL
    Compound: Mitomycin-C
    Antiproliferative activity against human HeLa cells after 6 days by MTT assay
    Antiproliferative activity against human HeLa cells after 6 days by MTT assay
    		[PMID: 22672798]
    HeLa ED50
    0.2 μg/mL
    Compound: mitomycin C
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    Cytotoxicity against human HeLa cells after 3 days by MTT assay
    		[PMID: 21115251]
    HeLa IC50
    0.015 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 12662110]
    HeLa IC50
    0.01 μg/mL
    Compound: Mytomycin C
    Cytotoxicity against human HeLa cells after 3 days by methylene blue assay
    Cytotoxicity against human HeLa cells after 3 days by methylene blue assay
    		[PMID: 9644081]
    HeLa IC50
    0.06 μg/mL
    Compound: Mitomycin
    Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
    Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay
    		[PMID: 22014827]
    HeLa IC50
    0.2 μM
    Compound: 2
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 35567964]
    HeLa IC50
    0.2 μM
    Compound: MMC; MCC
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 33581556]
    HeLa IC50
    0.27 μM
    Compound: MMC
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 20605274]
    HeLa IC50
    0.27 μM
    Compound: MMC, NSC-26980
    Cytotoxicity against human HeLa cells assessed as reduction in mean cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in mean cell viability after 72 hrs by MTT assay
    		[PMID: 22522008]
    HeLa IC50
    0.59 μM
    Compound: mitomycin C
    In vitro anticellular activity against HeLa S3 cells
    In vitro anticellular activity against HeLa S3 cells
    		[PMID: 8021919]
    HeLa IC50
    0.81 μM
    Compound: 1 (mitomycin C)
    In vitro anticellular activity against HeLa cells.
    In vitro anticellular activity against HeLa cells.
    		[PMID: 1495011]
    HeLa IC50
    1.1 μM
    Compound: mitomycin C
    In vitro anticellular activity against HeLa S3 cells; 0.59-1.1
    In vitro anticellular activity against HeLa S3 cells; 0.59-1.1
    		[PMID: 8021918]
    HeLa IC50
    1.13 μM
    Compound: MMC
    Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay
    		[PMID: 29475587]
    HeLa IC50
    1.4 μM
    Compound: mitomycin C
    In vitro anticellular activity against HeLa S3 cells; 0.82-1.4
    In vitro anticellular activity against HeLa S3 cells; 0.82-1.4
    		[PMID: 8021918]
    HeLa IC50
    1870 nM
    Compound: MC
    Antiproliferative activity against human HeLa cells after 48 hrs by resazurin reduction assay
    Antiproliferative activity against human HeLa cells after 48 hrs by resazurin reduction assay
    		[PMID: 26541587]
    HeLa IC50
    2 μM
    Compound: Mitomycin-C
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 25176329]
    HeLa IC50
    2 μM
    Compound: Mitomycin-c
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 24056146]
    HeLa IC50
    3 μM
    Compound: Mitomycin
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    Cytotoxicity against human HeLa cells after 48 hrs by SRB method
    		[PMID: 24913558]
    HeLa IC50
    3.3 μM
    Compound: mitomycin
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 19432411]
    HeLa IC50
    3.4 μM
    Compound: mitomycin C
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
    		[PMID: 22642381]
    HeLa IC50
    68 nM
    Compound: mitomycin C
    Cytotoxicity against human HeLa cells assessed as inhibition of colony formation after 5 to 8 days by colony assay
    Cytotoxicity against human HeLa cells assessed as inhibition of colony formation after 5 to 8 days by colony assay
    		[PMID: 11975488]
    HeLa S3 IC50
    0.52 μM
    Compound: Mitomycin C
    Cytotoxicity against human HeLa S3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa S3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35766102]
    Hep 3B2 IC50
    0.01 μg/mL
    Compound: Mytomycin C
    Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay
    Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay
    		[PMID: 9644081]
    HepG2 IC50
    0.13 μM
    Compound: Mitomycin
    Anticancer activity against human HepG2 cells by MTT assay
    Anticancer activity against human HepG2 cells by MTT assay
    		[PMID: 34128674]
    HepG2 IC50
    0.14 μg/mL
    Compound: Mitomycin
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay
    		[PMID: 23451797]
    HepG2 IC50
    0.27 μM
    Compound: Mitomycin C
    Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065).
    Compound was evaluated for the inhibition of cell proliferation of human hepatocellular carcinoma, HepG2 (ATCC HB8065).
    		10.1016/0960-894X(96)00418-0
    HepG2 IC50
    0.36 μg/mL
    Compound: 1
    in vitro inhibition of tumor cell growth in cultured HepG2 human tumor cell line
    in vitro inhibition of tumor cell growth in cultured HepG2 human tumor cell line
    		[PMID: 11585450]
    HepG2 IC50
    2.27 μM
    Compound: Mitomycin C
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34847663]
    HepG2 IC50
    2937 nM
    Compound: MC
    Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin reduction assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin reduction assay
    		[PMID: 26541587]
    HepG2 IC50
    32.63 μM
    Compound: Mitomycin C
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 31761382]
    HepG2 IC50
    5.4 μM
    Compound: Mitomycin
    Cytotoxicity against human HepG2 by MTT assay
    Cytotoxicity against human HepG2 by MTT assay
    		[PMID: 20968296]
    HepG2 IC50
    > 10 μM
    Compound: Mitomycin C
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 29280632]
    Hepatocyte EC50
    1.46 μM
    Compound: mitomycin
    Antiproliferative activity against human hepatocytes after 72 hrs by trypan blue exclusion assay
    Antiproliferative activity against human hepatocytes after 72 hrs by trypan blue exclusion assay
    		[PMID: 19674905]
    HuT78 IC50
    66 nM
    Compound: MC
    Antiproliferative activity against human HUT78 cells after 48 hrs by resazurin reduction assay
    Antiproliferative activity against human HUT78 cells after 48 hrs by resazurin reduction assay
    		[PMID: 26541587]
    Huh-7 GI50
    2 μM
    Compound: Mitomycin
    Growth inhibition of human HuH7 cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human HuH7 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    Jurkat IC50
    0.43 μM
    Compound: Mitomycin
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31490685]
    Jurkat IC50
    303 nM
    Compound: MC
    Antiproliferative activity against human Jurkat T cells in hypoxic condition after 48 hrs by resazurin reduction assay
    Antiproliferative activity against human Jurkat T cells in hypoxic condition after 48 hrs by resazurin reduction assay
    		[PMID: 26541587]
    Jurkat IC50
    578 nM
    Compound: MC
    Antiproliferative activity against human Jurkat T cells after 48 hrs by resazurin reduction assay
    Antiproliferative activity against human Jurkat T cells after 48 hrs by resazurin reduction assay
    		[PMID: 26541587]
    K562 IC50
    0.47 μM
    Compound: Mitomycin C
    Growth inhibition of human K562 cells after 24 to 72 hrs by MTT assay
    Growth inhibition of human K562 cells after 24 to 72 hrs by MTT assay
    		[PMID: 20117936]
    K562 IC50
    1 nM
    Compound: Mitomycin C
    In vitro inhibitory activity against K562 leukemia cells
    In vitro inhibitory activity against K562 leukemia cells
    		[PMID: 12699386]
    K562 IC50
    15.8 nM
    Compound: Mitomycin C
    In vitro inhibitory activity against K562 leukemia cells in the presence of pd2
    In vitro inhibitory activity against K562 leukemia cells in the presence of pd2
    		[PMID: 12699386]
    K562 IC50
    3.35 μg/mL
    Compound: Mitomycin
    Antitumor activity against human K562 cell line by MTT assay
    Antitumor activity against human K562 cell line by MTT assay
    		[PMID: 16455245]
    K562-Lucena 1 IC50
    2.75 μM
    Compound: Mitomycin C
    Growth inhibition of human K562-Lucena 1 cells after 24 to 72 hrs by MTT assay
    Growth inhibition of human K562-Lucena 1 cells after 24 to 72 hrs by MTT assay
    		[PMID: 20117936]
    KB ED50
    0.13 μg/mL
    Compound: mitomycin
    Cytotoxicity against human KB cells after 3 days by methylene blue staining
    Cytotoxicity against human KB cells after 3 days by methylene blue staining
    		[PMID: 16309320]
    KB ED50
    0.56 μg/mL
    Compound: Mitomycin
    Cytotoxicity against human KB cells after 72 hrs
    Cytotoxicity against human KB cells after 72 hrs
    		[PMID: 16643051]
    KB IC50
    0.015 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human KB cells
    Cytotoxicity against human KB cells
    		[PMID: 12662110]
    KB IC50
    0.01 μg/mL
    Compound: mitomycin C
    Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
    Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
    		[PMID: 11473432]
    KB IC50
    0.01 μg/mL
    Compound: mitomycin C
    Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
    Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
    		[PMID: 12502326]
    KB IC50
    0.08 μg/mL
    Compound: Mitomycin
    Cytotoxicity against human KB cells after 1 to 11 days by MTT assay
    Cytotoxicity against human KB cells after 1 to 11 days by MTT assay
    		[PMID: 22014827]
    KB IC50
    0.1 μg/mL
    Compound: 1
    in vitro anticancer activity against cultured KB(epidermoid) human tumor cell line
    in vitro anticancer activity against cultured KB(epidermoid) human tumor cell line
    		[PMID: 11585450]
    KB IC50
    0.4 μM
    Compound: Mitomycin C
    In vitro antitumor activity against human epidermoid carcinoma KB cells by MTT assay.
    In vitro antitumor activity against human epidermoid carcinoma KB cells by MTT assay.
    		10.1016/0960-894X(95)00353-U
    KB IC50
    0.4 μM
    Compound: Mytomycin C
    In vitro cytotoxicity determined against human epidermoid carcinoma KB cells by MTT assay
    In vitro cytotoxicity determined against human epidermoid carcinoma KB cells by MTT assay
    		10.1016/S0960-894X(97)00100-5
    KB IC50
    0.6 μM
    Compound: Mitomycin C
    Cytotoxicity against human KB cells after 3 days by SRB assay
    Cytotoxicity against human KB cells after 3 days by SRB assay
    		[PMID: 16038545]
    KB 3-1 IC50
    0.1 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
    		[PMID: 20149652]
    L02 IC50
    25.023 μM
    Compound: 1
    Cytotoxicity against human LO2 cells after 72 hrs by MTT assay
    Cytotoxicity against human LO2 cells after 72 hrs by MTT assay
    		[PMID: 28395199]
    L1210 IC50
    0.02 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against mouse L1210 cells
    Cytotoxicity against mouse L1210 cells
    		[PMID: 12662110]
    L1210 IC50
    0.09 μM
    Compound: 1
    Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.
    Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.
    		[PMID: 1906107]
    L1210 IC50
    0.6 μM
    Compound: Mitomycin C
    In vitro antitumor activity against murine lymphoma L1210 cells by MTT assay.
    In vitro antitumor activity against murine lymphoma L1210 cells by MTT assay.
    		10.1016/0960-894X(95)00353-U
    L1210 IC50
    0.6 μM
    Compound: Mytomycin C
    In vitro cytotoxicity determined against murine leukemia L1210 cells by MTT assay
    In vitro cytotoxicity determined against murine leukemia L1210 cells by MTT assay
    		10.1016/S0960-894X(97)00100-5
    L1210 IC50
    1.5 μM
    Compound: 1
    Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
    Inhibitory concentration on multidrug-resistant L1210 leukemia cells.
    		[PMID: 1906107]
    L6 ED50
    20.7 μM
    Compound: mitomycin C
    Cytotoxicity against human SCL6 cells by MTT assay
    Cytotoxicity against human SCL6 cells by MTT assay
    		[PMID: 12880314]
    M14 IC50
    0.47 μM
    Compound: Mitomycin C
    Cytotoxicity against human M14 cells after 72 hrs by MTS assay
    Cytotoxicity against human M14 cells after 72 hrs by MTS assay
    		[PMID: 26335269]
    MCF7 EC50
    0.96 μM
    Compound: Mitomycin
    Cytotoxicity against human MCF7 cells assessed as cell viability by tryptan blue staining method
    Cytotoxicity against human MCF7 cells assessed as cell viability by tryptan blue staining method
    		[PMID: 17950604]
    MCF7 EC50
    0.96 μM
    Compound: mitomycin
    Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay
    		[PMID: 19674905]
    MCF7 ED50
    0.09 μg/mL
    Compound: Mitomycin-C
    Antiproliferative activity against human MCF7 cells after 6 days by MTT assay
    Antiproliferative activity against human MCF7 cells after 6 days by MTT assay
    		[PMID: 22672798]
    MCF7 ED50
    0.14 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 20144547]
    MCF7 ED50
    0.1 μg/mL
    Compound: mitomycin C
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against human MCF7 cells after 3 days by MTT assay
    		[PMID: 21115251]
    MCF7 GI50
    2.5 μM
    Compound: Mitomycin
    Growth inhibition of human MCF7 cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human MCF7 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    MCF7 IC50
    0.06 μM
    Compound: Mitomycin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
    		[PMID: 27010926]
    MCF7 IC50
    0.2 μM
    Compound: MMC, mitomycin c
    Cytotoxicity against human MCF7 cells by Alamar blue assay
    Cytotoxicity against human MCF7 cells by Alamar blue assay
    		[PMID: 18037301]
    MCF7 IC50
    0.2 μM
    Compound: Mitomycin-C
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 25259515]
    MCF7 IC50
    0.2 μM
    Compound: mitomycin C
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay
    		[PMID: 18752870]
    MCF7 IC50
    0.45 μg/mL
    Compound: 1
    in vitro inhibition of tumor cell growth in cultured MCF-7 human tumor cell line
    in vitro inhibition of tumor cell growth in cultured MCF-7 human tumor cell line
    		[PMID: 11585450]
    MCF7 IC50
    0.93 μg/mL
    Compound: (21) mitomycin
    In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    MCF7 IC50
    1.2 μM
    Compound: MMC, mitomycin c
    Cytotoxicity against human MCF7 cells after 72 hrs
    Cytotoxicity against human MCF7 cells after 72 hrs
    		[PMID: 18037301]
    MCF7 IC50
    1.5 μM
    Compound: Mitomycin C
    Cytotoxicity against human MCF7 cells after 3 days by SRB assay
    Cytotoxicity against human MCF7 cells after 3 days by SRB assay
    		[PMID: 16038545]
    MCF7 IC50
    1.8 μM
    Compound: Mitomycin C
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 35766102]
    MCF7 IC50
    16.71 μM
    Compound: Mitomycin C
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
    		[PMID: 31761382]
    MCF7 IC50
    32.2 nM
    Compound: 1
    Antitumor potency on human breast MCF-7 cell lines.
    Antitumor potency on human breast MCF-7 cell lines.
    		[PMID: 1906109]
    MCF7 IC50
    5 μM
    Compound: MMC, mitomycin c
    Cytotoxicity against human MCF7 cells after 24 hrs
    Cytotoxicity against human MCF7 cells after 24 hrs
    		[PMID: 18037301]
    MDA-MB-231 EC50
    0.103 μM
    Compound: Mitomycin
    Cytotoxicity against human MDA-MB-231 cells overexpressing DT-diaphorase after 5 days
    Cytotoxicity against human MDA-MB-231 cells overexpressing DT-diaphorase after 5 days
    		[PMID: 24436995]
    MDA-MB-231 EC50
    1.25 μM
    Compound: Mitomycin
    Cytotoxicity against wild-type human MDA-MB-231 cells after 5 days
    Cytotoxicity against wild-type human MDA-MB-231 cells after 5 days
    		[PMID: 24436995]
    MDA-MB-231 IC50
    2.89 μM
    Compound: Mitomycin C
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34847663]
    MDA-MB-231 IC50
    4.4 μM
    Compound: Mitomycin C
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 29280632]
    MDA-MB-468 IC50
    0.27 μM
    Compound: Mitomycin C
    In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    MDA-MB-468 IC50
    0.5 μM
    Compound: Mitomycin C
    Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTS assay
    Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTS assay
    		[PMID: 26335269]
    MKN-74 GI50
    1.7 μM
    Compound: Mitomycin
    Growth inhibition of human MKN74 cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human MKN74 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    NCI-H226 IC50
    0.58 μM
    Compound: Mitomycin C
    Cytotoxicity against human NCI-H226 cells after 72 hrs by MTS assay
    Cytotoxicity against human NCI-H226 cells after 72 hrs by MTS assay
    		[PMID: 26335269]
    NCI-H23 IC50
    2 μM
    Compound: Mytomycin
    Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay
    Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay
    		[PMID: 23792352]
    NCI-H596 IC50
    11.969 μM
    Compound: 1
    Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay
    Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay
    		[PMID: 28395199]
    NIH3T3 IC50
    1.7 μM
    Compound: 1, Mitomycin C (MMC)
    Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay
    Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay
    		[PMID: 11855992]
    NUGC-4 ED50
    19.1 μM
    Compound: mitomycin C
    Cytotoxicity against human NUGC4 cells by MTT assay
    Cytotoxicity against human NUGC4 cells by MTT assay
    		[PMID: 12880314]
    P388 IC50
    0.01 μg/mL
    Compound: Mitomycin C (MMC)
    Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
    Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
    		10.1016/S0960-894X(97)00071-1
    P388 IC50
    0.02 μg/mL
    Compound: mitomycin C
    Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
    Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
    		[PMID: 8254344]
    P388 IC50
    0.06 μM
    Compound: Mitomycin
    Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 27010926]
    P388 IC50
    0.06 μg/mL
    Compound: Mitomycin C
    In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.
    In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.
    		[PMID: 9873721]
    P388 IC50
    0.15 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against mouse P388 cells by MTT assay
    Cytotoxicity against mouse P388 cells by MTT assay
    		[PMID: 17576066]
    P388 IC50
    1.5 μg/mL
    Compound: (21) mitomycin
    In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay
    In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay
    		[PMID: 12620075]
    P388 IC50
    3000 nM
    Compound: Mitomycin C
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    		[PMID: 2778449]
    P388 IC50
    50.8 nM
    Compound: 1
    Antitumor potency on P388 leukemia cells in culture
    Antitumor potency on P388 leukemia cells in culture
    		[PMID: 1906109]
    P388/ADR IC50
    535 nM
    Compound: Mitomycin C
    Evaluation of inhibitory activity against multidrug resistant P388 cells (P388/ADR) cells
    Evaluation of inhibitory activity against multidrug resistant P388 cells (P388/ADR) cells
    		[PMID: 8544183]
    P388/S IC50
    48 nM
    Compound: Mitomycin C
    Evaluation of inhibitory activity against drug sensitive P388 cells (P388/S) cells
    Evaluation of inhibitory activity against drug sensitive P388 cells (P388/S) cells
    		[PMID: 8544183]
    PBMC IC50
    4.03 μM
    Compound: Mitomycin C
    Growth inhibition of phytohemagglutinin-activated human PBMC cells after 24 to 72 hrs by MTT assay
    Growth inhibition of phytohemagglutinin-activated human PBMC cells after 24 to 72 hrs by MTT assay
    		[PMID: 20117936]
    PC-3 EC50
    0.14 μM
    Compound: Mitomycin
    Cytotoxicity against human PC3 cells assessed as cell viability by tryptan blue staining method
    Cytotoxicity against human PC3 cells assessed as cell viability by tryptan blue staining method
    		[PMID: 17950604]
    PC-3 EC50
    0.14 μM
    Compound: mitomycin
    Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay
    Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay
    		[PMID: 19674905]
    PC-3 IC50
    0.2 μM
    Compound: Mitomycin-C
    Cytotoxicity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    PC-3 IC50
    0.5 μM
    Compound: Mitomycin C
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 27089214]
    PC-3 IC50
    1.4 μM
    Compound: Mitomycin
    Cytotoxicity against human PC3 cells after 72 hrs by CCK-8 assay
    Cytotoxicity against human PC3 cells after 72 hrs by CCK-8 assay
    		[PMID: 26615890]
    PC-3 IC50
    1.4 μM
    Compound: Mitomycin C
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) PC3 cells by SRB assay
    		10.1007/s00044-010-9500-5
    PC-3 IC50
    1.5 μM
    Compound: Mitomycin-C
    Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0424-0
    PC-3 IC50
    1.5 μM
    Compound: Mitomycin-C
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
    		10.1039/C3MD00055A
    PC-3 IC50
    1.5 μM
    Compound: Mitomycin-C
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 25176329]
    PC-3 IC50
    1.5 μM
    Compound: Mitomycin-c
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 24056146]
    PC-3 IC50
    1.5 μM
    Compound: Mto-C
    Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
    Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 19939522]
    PC-3 IC50
    1.55 μg/mL
    Compound: 1
    in vitro inhibition of tumor cell growth in cultured PC-3 human tumor cell line
    in vitro inhibition of tumor cell growth in cultured PC-3 human tumor cell line
    		[PMID: 11585450]
    RKO IC50
    1.75 μg/mL
    Compound: Mitomycin
    Antitumor activity against human RKO cell line by MTT assay
    Antitumor activity against human RKO cell line by MTT assay
    		[PMID: 16455245]
    RPMI-8226 IC50
    200 nM
    Compound: mitomycin C
    In vitro inhibition of 7226/S myeloma cancer cell line
    In vitro inhibition of 7226/S myeloma cancer cell line
    		[PMID: 1920349]
    SF-295 IC50
    0.54 μM
    Compound: Mitomycin C
    Cytotoxicity against human SF295 cells after 72 hrs by MTS assay
    Cytotoxicity against human SF295 cells after 72 hrs by MTS assay
    		[PMID: 26335269]
    SF-539 IC50
    3.8 x 10-2 μM
    Compound: Mitomycin C
    Cytotoxicity against human SF539 cells after 72 hrs by MTS assay
    Cytotoxicity against human SF539 cells after 72 hrs by MTS assay
    		[PMID: 26335269]
    SGC-7901 IC50
    2.05 μM
    Compound: Mitomycin C
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay
    		[PMID: 23999045]
    SK-BR-3 IC50
    0.993 μM
    Compound: MMC
    Inhibition of cell growth was studied in human mammary adenocarcinoma (SKBR-3).
    Inhibition of cell growth was studied in human mammary adenocarcinoma (SKBR-3).
    		[PMID: 8709111]
    SK-BR-3 IC50
    1 μM
    Compound: Mitomycin
    Cytotoxicity against human SKBR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human SKBR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay
    		[PMID: 31490685]
    SK-OV-3 GI50
    0.1 μM
    Compound: Mitomycin
    Growth inhibition of human SKOV3 cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human SKOV3 cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    SK-OV-3 IC50
    0.18 μM
    Compound: Mitomycin C
    In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    SK-OV-3 IC50
    0.2 μM
    Compound: Mitomycin C
    The compound was evaluated for the cytotoxicity against human SKOV-3 (ovarian) tumor cell lines.
    The compound was evaluated for the cytotoxicity against human SKOV-3 (ovarian) tumor cell lines.
    		[PMID: 10698444]
    SMMC-7721 IC50
    2.44 μg/mL
    Compound: Mitomycin
    Antitumor activity against human SMMC7721 cell line by MTT assay
    Antitumor activity against human SMMC7721 cell line by MTT assay
    		[PMID: 16455245]
    SMMC-7721 IC50
    5.4 μM
    Compound: mitomycin
    Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay
    		[PMID: 19432411]
    SMMC-7721 IC50
    5.6 μM
    Compound: mitomycin C
    Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay
    Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay
    		[PMID: 22642381]
    SNU1 IC50
    2.32 μg/mL
    Compound: Mitomycin C
    In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.
    In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.
    		[PMID: 9873721]
    SW480 IC50
    0.79 μM
    Compound: Mitomycin C
    Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34847663]
    SW480 IC50
    7 nM
    Compound: mitomycin C
    In vitro inhibition of SW480 colon cancer cell line
    In vitro inhibition of SW480 colon cancer cell line
    		[PMID: 1920349]
    SW900 IC50
    0.24 μg/mL
    Compound: Mitomycin c
    Antitumor activity against SW900 human lung carcinoma cell line
    Antitumor activity against SW900 human lung carcinoma cell line
    		[PMID: 2754710]
    Sf9 IC50
    3 μg/mL
    Compound: mitomycin C
    Cytotoxicity against Spodoptera frugiperda Sf9 cells after 24 hrs by MTT assay
    Cytotoxicity against Spodoptera frugiperda Sf9 cells after 24 hrs by MTT assay
    		[PMID: 11277765]
    T47D IC50
    0.4 μM
    Compound: Mitomycin C
    In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay
    In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay
    		[PMID: 14980672]
    T47D IC50
    16970 nM
    Compound: MC
    Antiproliferative activity against human T47D cells after 48 hrs by resazurin reduction assay
    Antiproliferative activity against human T47D cells after 48 hrs by resazurin reduction assay
    		[PMID: 26541587]
    THP-1 IC50
    0.1 μM
    Compound: Mitomycin-C
    Cytotoxicity against human THP1 cells after 48 hrs by SRB assay
    Cytotoxicity against human THP1 cells after 48 hrs by SRB assay
    		[PMID: 25259515]
    THP-1 IC50
    0.5 μM
    Compound: Mitomycin-C
    Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    THP-1 IC50
    1.5 μM
    Compound: Mitomycin-C
    Cytotoxicity against Homo sapiens (human) THP1 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) THP1 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0424-0
    THP-1 IC50
    1.5 μM
    Compound: Mitomycin-C
    Cytotoxicity against human THP1 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
    Cytotoxicity against human THP1 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
    		10.1039/C3MD00055A
    U-87MG ATCC GI50
    1.8 μM
    Compound: Mitomycin
    Growth inhibition of human U87MG cells after 72 hrs by Cell-Titer Glo assay
    Growth inhibition of human U87MG cells after 72 hrs by Cell-Titer Glo assay
    		[PMID: 28682609]
    U-87MG ATCC IC50
    0.97 μg/mL
    Compound: 1
    in vitro anticancer activity against cultured U87MG (glioblastoma) human tumor cell line
    in vitro anticancer activity against cultured U87MG (glioblastoma) human tumor cell line
    		[PMID: 11585450]
    U2OS IC50
    8.45 μM
    Compound: Mitomycin C
    Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34847663]
    V79 IC50
    0.4 μM
    Compound: MMC
    Inhibitory concentration required to kill 50% of the cells was evaluated under anaerobic (N2) conditions from chinese hamster V79 cells.
    Inhibitory concentration required to kill 50% of the cells was evaluated under anaerobic (N2) conditions from chinese hamster V79 cells.
    		[PMID: 7966141]
    V79 IC50
    0.8 μM
    Compound: MMC
    Inhibitory concentration required to kill 50% of the cells was evaluated under aerobic conditions from chinese hamster V79 cells.
    Inhibitory concentration required to kill 50% of the cells was evaluated under aerobic conditions from chinese hamster V79 cells.
    		[PMID: 7966141]
    WiDr ED50
    0.15 μg/mL
    Compound: Mitomycin C
    Cytotoxicity against human WiDr cells by MTT assay
    Cytotoxicity against human WiDr cells by MTT assay
    		[PMID: 20144547]
    WiDr ED50
    0.18 μM
    Compound: mitomycin C
    Cytotoxicity against human WiDr cells by MTT assay
    Cytotoxicity against human WiDr cells by MTT assay
    		[PMID: 19061391]
    WiDr ED50
    0.35 μg/mL
    Compound: Mitomycin
    Cytotoxicity against human WiDr cells after 72 hrs
    Cytotoxicity against human WiDr cells after 72 hrs
    		[PMID: 16643051]
    WiDr IC50
    10 nM
    Compound: mitomycin C
    In vitro inhibition of WiDr colon cancer cell line
    In vitro inhibition of WiDr colon cancer cell line
    		[PMID: 1920349]
    WiDr IC50
    13 nM
    Compound: 1
    Antitumor potency on human colon WIDR cell lines.
    Antitumor potency on human colon WIDR cell lines.
    		[PMID: 1906109]
    体外研究
    (In Vitro)

    HCT116 (p53-/-) 细胞对丝裂霉素 C (Ametycine) 或单独的 TRAIL 的敏感性最低。然而，令人惊讶的是，MMC 和 TRAIL 的联合处理显著降低了细胞活力。尽管单独使用丝裂霉素 C 和 TRAIL 的效果适中，但丝裂霉素 C 大大增强了 TRAIL 对抑制细胞增殖的作用。单独使用丝裂霉素 C 和 TRAIL 处理分别诱导 9.5% 和 35.0% 的细胞凋亡。然而，丝裂霉素 C 和 TRAIL 联合处理可将细胞凋亡率提高至 66.6%[1]。
    丝裂霉素 C 是一种细胞毒性化疗剂，也会以 DNA 交联的形式引起 DNA 损伤作为多种 DNA 单加合物，已知可诱导 p53[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Mitomycin C 相关抗体:
    体内研究
    (In Vivo)

    携带异种移植 HCT116 (p53-/-) 结肠肿瘤和 HT-29 结肠肿瘤的小鼠每隔一段时间用丝裂霉素 C (阿米霉素；ip，1 mg/kg) 和 TRAIL (iv，100 μg) 处理天。用联合处理方案的 10 个连续周期处理动物。联合疗法显著抑制了肿瘤生长，并且不影响小鼠的体重，表明丝裂霉素 C 和 TRAIL 的处理组合具有良好的耐受性，并且在体内具有抗肿瘤活性[1]。
    膀胱内 Mitomycin C 滴注对体重有影响。在连续 3 次每周滴注 1 mg/mL 丝裂霉素 C 后，体重几乎没有增加，而与 MMC 处理的大鼠相比，其他 3 组大鼠的体重增加有统计学意义[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    334.33

    Formula

    C15H18N4O5
    CAS 号
    性状

    固体

    颜色

    Blue to black

    中文名称

    丝裂霉素 C；丝裂霉素；密吐霉素；自力霉素；嘧吡霉素；突变霉素
    结构分类
    初始来源

    Streptomyces
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : 50 mg/mL (149.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.9911 mL 14.9553 mL 29.9106 mL
    5 mM 0.5982 mL 2.9911 mL 5.9821 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (6.22 mM); 澄清溶液

      此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

      生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (6.22 mM); 澄清溶液

      此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

      2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    请输入您的动物体内配方组成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
    连续给药周期超过半月以上，请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.70%

    COA (295 KB) HNMR (261 KB) LCMS (275 KB)

    产品使用指南 (1538 KB)
    参考文献
    Cell Assay
    [1]

    Colon adenocarcinoma HCT116 and HT-29 human colon cancer cells are used. The CellTiter-Glo Luminescent Cell Viability Assay is used to measure cell viability, which use a unique, stable form of luciferase to measure ATP as an indicator of viable cells, and the luminescent signal produced is proportional to the number of viable cells present in culture. Cells are pretreated with Mitomycin C (5 μM) for 12 h or 24 h, and then exposed to different concentrations of TRAIL for 12 h. An equal volume (100 μL) of CellTiter-GloTM reagent is added and the solution is mixed gently for 2 min on an orbital shaker. Mixture is incubated at room temperature for 10 min to allow luminescent signal to stabilize, and then imaging is performed using the Xenogen IVIS system to quantify the cell viability[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1][3]

    Mice[1]
    Four- to 6-wk-old NCr nude mice are treated with Mitomycin C (1 mg/kg) by intraperitoneal injection for 24 h, followed by one intravenous dose of purified rhTRAIL (100 μg). As a negative control, a subset of the mice are injected (i.p. and i.v.) with saline (vehicle) at the same frequency of treatment. Animals are treated for 3 consecutive weeks. The tumor size is monitored every week using caliper measurements of the tumor volume.
    Rats[3]
    Young adult female Wistar rats at age 13 weeks with a median weight of 217 g (range 187 to 255) are randomized into 4 groups of 10 each, namely a normal group with no instillations, an NaCl 0.9% or placebo group that received instillations with the solvent of the chemotherapeutic agent, Mitomycin C (1 mg/mL) group.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    Mitomycin C 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.9911 mL 14.9553 mL 29.9106 mL 74.7764 mL
    5 mM 0.5982 mL 2.9911 mL 5.9821 mL 14.9553 mL
    10 mM 0.2991 mL 1.4955 mL 2.9911 mL 7.4776 mL
    15 mM 0.1994 mL 0.9970 mL 1.9940 mL 4.9851 mL
    20 mM 0.1496 mL 0.7478 mL 1.4955 mL 3.7388 mL
    25 mM 0.1196 mL 0.5982 mL 1.1964 mL 2.9911 mL
    30 mM 0.0997 mL 0.4985 mL 0.9970 mL 2.4925 mL
    40 mM 0.0748 mL 0.3739 mL 0.7478 mL 1.8694 mL
    50 mM 0.0598 mL 0.2991 mL 0.5982 mL 1.4955 mL
    60 mM 0.0499 mL 0.2493 mL 0.4985 mL 1.2463 mL
    80 mM 0.0374 mL 0.1869 mL 0.3739 mL 0.9347 mL
    100 mM 0.0299 mL 0.1496 mL 0.2991 mL 0.7478 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Mitomycin C50-07-7Ametycine丝裂霉素 C丝裂霉素密吐霉素自力霉素嘧吡霉素突变霉素DNA Alkylator/CrosslinkerDNA/RNA SynthesisADC PayloadBacterialApoptosisAntibioticADC CytotoxinDNAcross-linkingagentdamagingantitumorantibioticInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Mitomycin C
    目录号：
    HY-13316
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z